Abstract
PURPOSE: To evaluate outcomes of high myopic LASIK using the MEL 80 excimer laser (Carl Zeiss Meditec, Jena, Germany). METHODS: Retrospective analysis of 479 consecutive high myopic LASIK procedures (318 patients) using the MEL 80 excimer laser and VisuMax femtosecond laser (Carl Zeiss Meditec) in 77% of cases or zero compression Hansatome microkeratome (Bausch & Lomb, Rochester, NY) in 23% of cases. Inclusion criteria were preoperative spherical equivalent refraction (SEQ) of between -8.00 and -14.25 diopters (D) and corrected distance visual acuity (CDVA) of 20/20 or better. Patients were observed for a minimum of 1 year. Flap thickness was between 80 and 160 μm and optical zone was between 5.75 and 6.50 mm. Standard outcomes analysis was performed. RESULTS: Mean attempted SEQ was -9.39 ± 1.22 D (range: -8.00 to -14.18 D) and mean cylinder was -1.03 ± 0.84 D (range: 0.00 to -4.50 D). Mean age was 37 ± 9 years (range: 21 to 60 years) with 54% female patients. Postoperative SEQ was ±0.50 D in 55% and ±1.00 D in 83% of eyes after primary treatment. After re-treatment, 69% of eyes were within ±0.50 D and 95% were within ±1.00 D. UDVA was 20/20 or better in 89% of eyes after final treatment. One line of CDVA was lost in 3% of eyes and no eyes lost two or more lines. Statistically significant increases (P < .001) were measured in contrast sensitivity (CSV-1000) at 12 and 18 cycles per degree. CONCLUSIONS: The MEL 80 excimer laser was found to achieve high efficacy and safety for treatment of high myopia between -8.00 and -14.25 D and up to -4.50 D of cylinder.
Original language | English |
---|---|
Pages (from-to) | 298-304 |
Number of pages | 7 |
Journal | Journal of Refractive Surgery |
Volume | 32 |
Issue number | 5 |
Early online date | 29 Feb 2016 |
DOIs | |
Publication status | E-pub ahead of print - 29 Feb 2016 |
Bibliographical note
Funding Information:Dr. Leung is a speaker for and has received material support in the form of equipment and a research grant from Carl Zeiss Meditec. The remaining authors have no financial or proprietary interest in the materials presented herein.